Press release content from PR Newswire. The AP news staff was not involved in its creation.
NaviFUS begins FUS combined with radiotherapy clinical trial for the treatment of terminal primary brain tumors
August 4, 2021 GMT
TAIPEI, Aug. 3, 2021 /PRNewswire/ NaviFUS’ focused ultrasound (FUS) therapy system (NaviFUS®) was recently approved for use in a new clinical trial by the Taiwan Food and Drug Administration (TFDA). It will be initiated shortly at Linkou Chang Gung Memorial Hospital. The trial will investigate the “synergy” that FUS-mediated opening of the blood-brain barrier (BBB) has on improving the therapeutic effect of radiotherapy treatment in patients with end-stage primary brain tumors. Despite suffering from repeating surgeries, radiotherapy, and chemotherapy, most of these patients will eventually face tumor recurrence. Currently, while there may not be any effective treatments guaranteed to prolong survival, NaviFUS hopes that this upcoming clinical trial can